Treatment with anti-ErbB2 antibodies
AssigneeGenentech, Inc.
InventorsVirginia E. Paton, Steven Shak, Susan D. Hellmann
Life of this patent
Estimating the term…
Abstract
The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
Claims33
A method for the treatment of a human patient susceptible to or diagnosed with a disorder characterized by overexpression of ErbB2 receptor, comprising administering an effective amount of a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other patient.
An article of manufacture, comprising a container, a composition within the container comprising an anti-ErbB2 antibody, and a package insert containing instructions to avoid the use of anthracycline-type chemotherapeutics in combination with said composition.
A method for the treatment of a human patient with a malignant tumor or cancer that expresses ErbB2 receptor, comprising administering a combination of an antibody that binds ErbB2, a taxoid and a further chemotherapeutic agent to the human patient in an amount effective to extend the time to disease progression in the human patient.
The method of 20 wherein the further chemotherapeutic agent is gemcitabine.
A method for the treatment of a human patient with metastatic breast cancer, comprising administering a combination of an antibody that binds ErbB2, a taxoid and a further chemotherapeutic agent, in the absence of an anthracycline derivative, to the human patient in an amount effective to extend the time to disease progression in the human patient.
A method for the treatment of a human patient with a malignant tumor or cancer that expresses ErbB2 receptor, comprising administering a combination of an antibody that binds ErbB2, a taxoid and carboplatin to the human patient in an amount effective to extend the time to disease progression in the human patient.
Dependencies are inferred from the claim text.